Becton Dickinson pledges $19 billion US investment in tariff deal with Trump administration

Becton Dickinson has agreed to invest $19 billion in the United States over several years, earmarking $3 billion to expand domestic manufacturing sites. In exchange, the medical device maker secures relief from future Section 232 tariffs. The deal is part of a broader Trump administration strategy leveraging tariff threats to force healthcare companies to onshore production. Other major drugmakers, including Pfizer, AstraZeneca, and Eli Lilly, have similarly pledged billions in domestic investments to shield themselves from trade penalties.

Becton Dickinson's tariff agreement with Trump

• ▪Becton Dickinson entered an agreement with the Trump administration to invest $19 billion in the United States over several years in exchange for relief from future tariffs.
• ▪Becton Dickinson is not currently quantifying the financial impact of the agreement because final tariff rates, product scope, and timing have not been determined.
• ▪The agreement ties Becton Dickinson's manufacturing commitments to relief from future Section 232 tariffs on covered products and inputs, subject to meeting agreed milestones.

Becton Dickinson's domestic manufacturing plans

• ▪Becton Dickinson plans to direct $3 billion of its $19 billion investment to expand domestic manufacturing across strategic sites in the United States.
• ▪Becton Dickinson plans to expand U.S. production by about 5 billion essential medical consumables annually, raising its domestic supply share of these items to roughly 80%.
• ▪Becton Dickinson plans to manufacture all needles used in the United States domestically using American-made steel.

Nebraska manufacturing investments

• ▪Becton Dickinson previously announced a $110 million investment in Columbus, Nebraska, to expand prefillable syringe and cannula production, with supply expected to begin in mid-2026.
• ▪President Donald Trump stated on October 5, 2026, that Becton Dickinson agreed to direct more than $1 billion of its investment to Nebraska.

Healthcare industry investments

• ▪Drugmakers have announced roughly $500 billion in United States investments to strengthen infrastructure, mitigate supply-chain risks, and reassure investors.
• ▪The Trump administration is using tariff threats to spur domestic healthcare manufacturing, prompting major drugmakers and medical device companies to pledge billions for U.S. facilities.

Investment pledges by other drugmakers

• ▪Pfizer reached a deal with President Donald Trump to invest $70 billion in domestic research, development, and manufacturing in exchange for a three-year tariff grace period.
• ▪AstraZeneca plans to invest $50 billion in United States manufacturing by 2030, including a new drug substance facility in Virginia and expansions in five other states.
• ▪Eli Lilly plans to raise its United States investments by 25% to a total of $55 billion over four years, which includes building four new plants.

US-Thailand trade negotiations

• ▪The United States government seeks to finalize and sign a tariff agreement with Thailand during President Donald Trump's upcoming trip to Asia, potentially in November 2026.
• ▪The Thai Commerce Ministry stated that negotiations for the tariff agreement with the United States are in their final stages.

Debatable claims

• ▪The Trump administration's practice of trading tariff exemptions for corporate investment pledges is justified
• ▪Tariff threats are an effective way to rebuild domestic healthcare manufacturing
• ▪The U.S. government should exempt all essential medical supplies from tariffs unconditionally
• ▪Forcing domestic production of medical consumables will increase healthcare costs for American patients